Ongoing Studies

Psoriasis Study
(Eli Lilly and Company, 24 Weeks)

Sadick Research Group is conducting a clinical study of adult patients receiving an injectable treatment for plaque psoriasis.

Study Details

Phase: 4
Gender: Male and Female
Minimum Age: 18 Years Old
Maximum Age: N/A
Facility Type: Outpatient
Stipend Range: Up to $750 Upon Study Completion
Study Length: 24 weeks
Sponsor: Eli Lilly & Company

Study Description

This is a 24-week, randomized double-blind study for adults with moderate-to-severe plaque psoriasis. This study is comparing the efficacy and safety of ixekizumab to guselkumab. There are 15 office visits throughout the study and can include a physical exam, urine sampling, ECGs, blood draws, and assessments by qualified professionals and other assessments which will be reviewed in detail at your screening visit. All services are provided at no cost.

Inclusion and Exclusion Criteria

Eligible male and female participants will be 18 years of age or older, have a stable diagnosis of plaque psoriasis for at least 6 months. Female subjects cannot plan to be pregnant or breast feeding during the study. Subjects must be available for the 15 office visits during the study and be willing to comply with all study instructions. Several other restrictions and criteria may apply that the study doctor will review with you to determine if you qualify to enter the study.

Other Trial Details

  • Physical exam and assessments of study condition to be provided at no cost by an experienced provider.
  • No insurance necessary.
  • Compensation will be provided at the end of study participation. 


Psoriasis Study (Eli Lilly & Co., 24 Weeks)

Contact Information


Psoriasis Study (Eli Lilly & Co. 24 Weeks)

Interested in our research? Join our newsletter

Send us a message

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt
Cellulite, Orange Peel